You just read:

Trovagene Submits Protocol to FDA for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga® for Metastatic Castration-Resistant Prostate Cancer

News provided by

Trovagene, Inc.

Dec 14, 2017, 08:00 ET